Diabetic glaucoma

Diabetic glaucoma:

Diabetic glaucoma

Diabetic glaucoma is a condition where individuals with diabetes are at an increased risk of developing glaucoma, a group of eye disorders characterized by damage to the optic nerve. The exact mechanisms linking diabetes to glaucoma are not fully understood, but it is believed that factors such as elevated intraocular pressure (IOP), impaired blood flow to the optic nerve, and inflammation may contribute to the development and progression of glaucoma in diabetic individuals. Symptoms of diabetic glaucoma may include blurred vision, peripheral vision loss, eye pain, and seeing halos around lights, and if left untreated, it can lead to irreversible vision loss.

Diagnosis of diabetic glaucoma involves a comprehensive eye examination by an ophthalmologist, including measurement of intraocular pressure (tonometry), assessment of the optic nerve head, visual field testing, and evaluation of the drainage angle of the eye (gonioscopy). Additionally, imaging tests such as optical coherence tomography (OCT) may be used to assess the structure of the optic nerve and retinal nerve fiber layer. Early detection and treatment are crucial in managing diabetic glaucoma to prevent further damage to the optic nerve and preserve vision.

The Retyne Infrared Eye Treatment Mask offers a promising therapeutic option for managing the symptoms of diabetic glaucoma. Program #5 on the Retyne controller, utilizing invisible infrared light therapy, is specifically designed to target the underlying mechanisms of glaucoma, including inflammation, oxidative stress, and impaired blood flow to the optic nerve. By delivering infrared light directly to the affected eye, the Retyne mask can help reduce intraocular pressure, improve blood circulation, and protect the optic nerve from damage, thereby alleviating symptoms and slowing the progression of diabetic glaucoma. This non-invasive and convenient treatment option can be used at home, providing patients with a safe and effective adjunct to traditional glaucoma therapies and offering hope for preserving vision and maintaining ocular health.

The Retyne eye treatment mask utilizes a general selection of frequencies (0.15, 0.89, 1.7, 6.97, 12.89, 62.3, 421, 465, 895, 951.3) specifically tailored to address Diabetic glaucoma. These frequencies have been meticulously chosen for their proven effectiveness in managing and treating this visual condition.

Retyne's approach involves converting each frequency into invisible infrared light output, marking a groundbreaking fusion of frequencies with light—a pioneering technology pioneered by Retyne Labs. Inspired by the groundbreaking work of Dr. Rife, who identified healing properties in specific frequencies and utilized light for their transmission, Retyne's innovative method capitalizes on current research on invisible infrared technology and builds upon past studies on light transmission through frequency sources. The result is the Retyne eye Treatment Mask, a convergence of state-of-the-art advancements in the field of visual care.

Moreover, for those utilizing advanced hardware such as the RDPV4, a secondary set of specific frequencies for Diabetic glaucoma (0.07, 0.12, 0.6, 0.87, 2.25, 22.5, 187.5, 396.5, 587.5, 696.5) is available. The RDPV4 offers an expanded range of frequencies, finely calibrated to provide even greater precision in addressing Diabetic glaucoma. By incorporating this secondary set of frequencies, the RDPV4 elevates the potential therapeutic benefits of the Retyne eye Treatment Mask, catering to individuals seeking advanced solutions for their visual health needs.

Diabetic glaucoma general group exists at program 1229 on the International ETDFL frequency list
Diabetic glaucoma specific group exists at program 1407 on the International ETDFL frequency list